Category: New Technology: Stones

MP5-17 - The added value of a single-use scope for double-J stent removal from the perspective of urologists at high volume centres

Fri, Sep 21
10:00 AM - 12:00 PM

Introduction & Objective :

Emerging technologies have the potential to positively impact patient care; but also hold implications for healthcare organizations and professionals, and pose challenges for decision-makers in assessing their value for money. Isiris-a is a novel single use digital flexible cystoscope with an incorporated grasper for double J removal. Experience with its use has rendered satisfying results. However, its cost-benefit remains unknown. This study explores the perceived added value of this Single Use Double-J Removal Solution (SUDRS)in usual clinical practice from the perspective of medical experts in Urology. This is part 1 of a Dutch study that seeks to establish the costs-benefits of incorporating this device into the health service delivery system.


Methods : Based on a literature review, open-ended questions were developed and used to conduct 6 semi-structured, 1 hour interviews with staff [clinicians (n=4), hospital managers (n=1) and a head of a hospital sterilisation and reprocessing department (n=1)] at the Amsterdam Medical Center, a hospital with a high turnaround of patients who need a stent removal. All interviewees had experience with the SUDRS. Interviews were audio-tape recorded and transcribed. Emerging features were summarised by researchers.


Results : Participants all agreed that the most important differential value of Isiris-a are the simplicity it adds to the performance of the stent removal procedure, and its potential to improve the organization of the unit. It is a single operator device; it may allow a shift on staff needs (from physician to specialist nurse); a shift on removal place needs (from endoscopy room to outpatient clinic or bedside), and a shift on infrastructure needs (from a video-tower, reusable endoscope requiring cleaning and sterilisation to a single-use device). According to experts,  the device is suitable for most patients, saves time from extra appointments, is 100 % sterile, and patients may have a less stressful experience with a system that looks friendlier, smaller, and of easier use. Experts emphasized that important steps in the reprocessing of the currently used cystoscopes are omitted with the SUDRS.


Conclusions : Experts have identified several differential features of Isiris-a of significant value in clinical practice. Evidence on differences in cost per patient per procedure with the SUDRS compared to current practice is needed in order to more comprehensively gauge the worth of its adoption.

Joyce Baard

Urologist
AMC University Hospital, Urology, Amsterdam, The Netherlands
Amsterdam, Noord-Holland, Netherlands

Roan Spermon

Urologist
Urologist
Diakonessenhuis, Utrecht, Netherlands

Silvia Paz

Researcher
T4Communications
Benicassim, Comunidad Valenciana, Spain

Silvia Paz Ruiz, MD, obtained a medical degree qualification (MD) from the University of Buenos Aires in Argentina. She was an Honorary Research Fellow at the University of Sheffield, UK (MMedSci in Palliative Care), gained a Master Degree in Research Methodology from the University Jaume I, Spain and obtained an Executive Programme certificate from the Entrepreneurship Development Program by the MIT Sloan School of Management, Boston, US.
Silvia has over 10 years’ experience working for leading global pharmaceutical, nutrition, biotechnology and medical device companies both as a consultant and as a researcher, writer and trainer. She has developed clinical, research and consultancy work nationally, in Spain, and internationally in different European countries, and has a broad business and consultancy background acquired through different management level roles held in hospitals, initially, and in consultancy companies, later. As a consultant she has led and delivered projects across a breadth of different areas including market access, health outcomes research, patients reported outcomes, patients, payers and stakeholders engagement, business case development, benchmarking, environment and competitors analysis, and pricing definition and management.
She provides value proposition projects consulting, health economics, health outcomes and market access consulting, medical and regulatory writing, publication planning and strategic competitive analyses in diverse therapeutic areas including rare diseases, oncology, cardiovascular, metabolic, diabetes, nutrition, chronic inflammatory illnesses, degenerative diseases of the nervous system and other neurologic disorders, gastrointestinal disorders, infectious diseases, allergies, musculoskeletal disorders, psychiatric disorders, pain, respiratory disorders, rheumatologic disorders, and fertility. Current activities include global value dossiers development, market access planning, continuing medical education programs, literature reviews and analysis, manuscripts for peer-reviewed journals, monographs, reviews, and white papers, training courses delivery and materials, stakeholders’ engagement, advisory boards, and summaries of key findings presented at professional conferences, advisory boards, and symposia.